{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T06:10:10Z","timestamp":1777183810037,"version":"3.51.4"},"reference-count":35,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1016\/j.ygyno.2011.04.041","type":"journal-article","created":{"date-parts":[[2011,6,24]],"date-time":"2011-06-24T20:26:43Z","timestamp":1308947203000},"page":"521-526","source":"Crossref","is-referenced-by-count":57,"title":["The impact of disease distribution on survival in patients with stage III epithelial ovarian cancer cytoreduced to microscopic residual: A gynecologic oncology group study"],"prefix":"10.1016","volume":"122","author":[{"given":"Chad A.","family":"Hamilton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Austin","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caela","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas C.","family":"Krivak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John H.","family":"Farley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mildred R.","family":"Chernofsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael P.","family":"Stany","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. Scott","family":"Rose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurie","family":"Markman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert F.","family":"Ozols","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah K.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. Larry","family":"Maxwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2011.04.041_bb0005","doi-asserted-by":"crossref","unstructured":"Jemal A, Siegel R, Xu J, Ward E: Cancer Statistics, 2010. CA Cancer J Clin, 2010.","DOI":"10.3322\/caac.20073"},{"key":"10.1016\/j.ygyno.2011.04.041_bb0010","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.20.5.1248","article-title":"Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis","volume":"20","author":"Bristow","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.04.041_bb0015","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1200\/JCO.2007.11.0932","article-title":"Role of surgery in ovarian carcinoma","volume":"25","author":"Fader","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.04.041_bb0020","first-page":"101","article-title":"Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma","volume":"42","author":"Griffiths","year":"1975","journal-title":"Natl Cancer Inst Monogr"},{"key":"10.1016\/j.ygyno.2011.04.041_bb0025","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ygyno.2006.07.004","article-title":"\u201cOptimal\u201d cytoreduction for advanced epithelial ovarian cancer: a commentary","volume":"103","author":"Eisenkop","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.04.041_bb0030","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1053\/j.seminoncol.2008.07.007","article-title":"Progress in gynecologic cancer research: the Gynecologic Oncology Group experience","volume":"35","author":"Omura","year":"2008","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ygyno.2011.04.041_bb0035","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1200\/JCO.2006.10.2517","article-title":"Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study","volume":"25","author":"Winter","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.04.041_bb0040","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/01.AOG.0000192407.04428.bb","article-title":"Aggressive surgical effort and improved survival in advanced-stage ovarian cancer","volume":"107","author":"Aletti","year":"2006","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ygyno.2011.04.041_bb0045","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S0090-8258(03)00278-6","article-title":"Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study","volume":"90","author":"Eisenkop","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.04.041_bb0050","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.ygyno.2006.03.051","article-title":"What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?","volume":"103","author":"Chi","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.04.041_bb0055","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1245\/s10434-009-0787-8","article-title":"Prognostic impact of additional extended surgical procedures in advanced-stage primary ovarian cancer","volume":"17","author":"Kommoss","year":"2010","journal-title":"Ann Surg Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.ygyno.2011.04.041_bb0060","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1111\/IGC.0b013e3181bffb3f","article-title":"Prognostic factors for complete debulking in first- and second-line ovarian cancer","volume":"19","author":"Harter","year":"2009","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2011.04.041_bb0065","doi-asserted-by":"crossref","first-page":"8802","DOI":"10.1200\/JCO.2005.02.1287","article-title":"Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 Trial","volume":"23","author":"Crawford","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.04.041_bb0070","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0090-8258(92)90100-W","article-title":"The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study","volume":"47","author":"Hoskins","year":"1992","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.04.041_bb0075","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.ygyno.2008.07.058","article-title":"Cytoreduction vs. neoadjuvant chemotherapy for ovarian cancer","volume":"111","author":"Chi","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.04.041_bb0080","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2011.04.041_bb0085","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","volume":"19","author":"Markman","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.04.041_bb0090","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.04.041_bb0095","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2307\/2281868","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.ygyno.2011.04.041_bb0100","first-page":"163","article-title":"Evaluation of survival data and two new rank order statistics arising in its consideration","volume":"50","author":"Mantel","year":"1966","journal-title":"Cancer Chemother Rep"},{"key":"10.1016\/j.ygyno.2011.04.041_bb0105","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life tables (with discussion)","volume":"34","author":"Cox","year":"1972","journal-title":"J R Stat Soc Series B"},{"key":"10.1016\/j.ygyno.2011.04.041_bb0110","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1200\/JCO.2006.06.0111","article-title":"Importance of surgical aggressiveness in advanced ovarian cancer","volume":"24","author":"Aletti","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.04.041_bb0115","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1200\/JCO.2005.05.4890","article-title":"Aggressive surgery and ovarian cancer","volume":"24","author":"Chi","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.04.041_bb0120","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1200\/JCO.2006.05.8701","article-title":"Aggressive surgery and ovarian cancer; authors reply","volume":"24","author":"Crawford","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.04.041_bb0125","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ygyno.2009.03.018","article-title":"Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm","volume":"114","author":"Chi","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.04.041_bb0130","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ygyno.2007.10.001","article-title":"The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer","volume":"108","author":"Zivanovic","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.04.041_bb0135","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1200\/JCO.2007.13.1953","article-title":"Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study","volume":"26","author":"Winter","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.04.041_bb0140","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/cncr.24149","volume":"115","author":"du Bois","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2011.04.041_bb0145","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.ygyno.2006.06.028","article-title":"The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC\u2013IV epithelial ovarian cancer","volume":"103","author":"Eisenhauer","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.04.041_bb0150","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ygyno.2009.11.022","article-title":"The effect of primary cytoreduction on outcomes of patients with FIGO stage IIIC ovarian cancer stratified by the initial tumor burden in the upper abdomen cephalad to the greater omentum","volume":"116","author":"Zivanovic","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.04.041_bb0155","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.ajog.2004.02.005","article-title":"Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays","volume":"190","author":"Berchuck","year":"2004","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ygyno.2011.04.041_bb0160","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1006\/gyno.2000.5926","article-title":"A critique of surgical cytoreduction in advanced ovarian cancer","volume":"78","author":"Covens","year":"2000","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.04.041_bb0165","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.1200\/JCO.2007.11.8992","article-title":"Concept of optimal surgical cytoreduction in advanced ovarian cancer: a brief critique and a call for action","volume":"25","author":"Markman","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.04.041_bb0170","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ygyno.2006.11.025","article-title":"Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease","volume":"105","author":"Hou","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.04.041_bb0175","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1002\/cncr.24084","article-title":"The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma: a Gynecologic Oncology Group study","volume":"115","author":"Zorn","year":"2009","journal-title":"Cancer"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825811003428?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825811003428?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T16:19:09Z","timestamp":1741277949000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825811003428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["S0090825811003428"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2011.04.041","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9]]}}}